CN114246949B - Use of ULK1 activators for the prevention and/or treatment of hearing impairment - Google Patents
Use of ULK1 activators for the prevention and/or treatment of hearing impairment Download PDFInfo
- Publication number
- CN114246949B CN114246949B CN202111530607.7A CN202111530607A CN114246949B CN 114246949 B CN114246949 B CN 114246949B CN 202111530607 A CN202111530607 A CN 202111530607A CN 114246949 B CN114246949 B CN 114246949B
- Authority
- CN
- China
- Prior art keywords
- noise
- hearing
- ulk1
- hearing impairment
- induced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 69
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 title abstract description 48
- 102000016956 Autophagy-Related Protein-1 Homolog Human genes 0.000 title abstract description 48
- 239000012190 activator Substances 0.000 title abstract description 28
- 238000011282 treatment Methods 0.000 title abstract description 25
- 230000002265 prevention Effects 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 33
- 210000003477 cochlea Anatomy 0.000 claims abstract description 32
- 230000004900 autophagic degradation Effects 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 22
- 206010011878 Deafness Diseases 0.000 claims abstract description 15
- 210000002569 neuron Anatomy 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 230000004224 protection Effects 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 20
- 230000009467 reduction Effects 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 12
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 231100000895 deafness Toxicity 0.000 claims description 7
- 210000003030 auditory receptor cell Anatomy 0.000 claims description 6
- 210000000225 synapse Anatomy 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002503 metabolic effect Effects 0.000 claims description 3
- 231100000199 ototoxic Toxicity 0.000 claims description 3
- 230000002970 ototoxic effect Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 231100000888 hearing loss Toxicity 0.000 abstract description 8
- 230000010370 hearing loss Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 206010011903 Deafness traumatic Diseases 0.000 abstract description 3
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000010172 mouse model Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 67
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 238000000034 method Methods 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 14
- 230000006378 damage Effects 0.000 description 12
- 210000004957 autophagosome Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 9
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 210000000067 inner hair cell Anatomy 0.000 description 9
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 9
- 229950006874 kainic acid Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000004126 nerve fiber Anatomy 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- -1 1-methyl-4-phenylpyridine ion Chemical class 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000003027 ear inner Anatomy 0.000 description 7
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
- 108010054624 red fluorescent protein Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- 210000002469 basement membrane Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 210000003712 lysosome Anatomy 0.000 description 4
- 230000001868 lysosomic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000000133 brain stem Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000001323 spiral ganglion Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010063602 Exposure to noise Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032041 Hearing impaired Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010036626 Presbyacusis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000000721 basilar membrane Anatomy 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002768 hair cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000009800 presbycusis Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100023898 Autophagy-related protein 101 Human genes 0.000 description 1
- 102100020689 Autophagy-related protein 13 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000905423 Homo sapiens Autophagy-related protein 101 Proteins 0.000 description 1
- 101000785138 Homo sapiens Autophagy-related protein 13 Proteins 0.000 description 1
- 101100101731 Homo sapiens ULK1 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 101710171587 Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 1
- 102000026889 Myosin VIIa Human genes 0.000 description 1
- 108010009047 Myosin VIIa Proteins 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100036328 Pejvakin Human genes 0.000 description 1
- 101710135791 Pejvakin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101710189963 RB1-inducible coiled-coil protein 1 Proteins 0.000 description 1
- 102100023588 RB1-inducible coiled-coil protein 1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000014646 age-related hearing impairment Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 210000003926 auditory cortex Anatomy 0.000 description 1
- 230000005033 autophagosome formation Effects 0.000 description 1
- 230000007747 autophagy signaling pathway Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960004774 citicoline sodium Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000002266 hair cells auditory Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960003642 nicergoline Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YWAFNFGRBBBSPD-OCMLZEEQSA-M sodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-OCMLZEEQSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to the field of biomedicine, and discloses application of a ULK1 activator in preparation of a medicine for preventing and/or treating hearing loss, wherein the ULK1 activator comprises BL-918. According to the invention, through carrying out noise exposure experimental tests on a mouse model, the test proves that the activity of ULK1 can be enhanced by administering the ULK1 activating agent such as BL-918 before noise exposure, the autophagy level in spiral neurons in cochlea can be enhanced, the hearing threshold shift caused by noise can be reduced, and the like, and the noise-induced hearing loss prevention effect is good for noise. As an ingredient of hearing protection, the ULK1 activator can also give an effective treatment after hearing impairment. The invention also discloses a pharmaceutical composition containing the ULK1 activator. The invention provides a new idea for preventing and treating hearing impairment, thereby having wide clinical application prospect.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to application of an ULK1 activator in preventing and/or treating hearing loss, and more particularly to application of BL-918 in preventing and/or treating noise-induced hearing loss.
Background
Deafness is the most prevalent sensory organ disability worldwide, and as of 2020, 4.3 million people worldwide have suffered from moderate and above hearing impairment. Auditory abnormalities cause speech disorders, cognitive impairment, psychological seals and self-disfunction of patients, and place a heavy burden on families and society.
Of these, presbycusis (ARHL), an age-related hearing impairment, remains a major factor in causing hearing impairment. In the hearing impaired population, over 42% of the population over 60 years old is present. Presbycusis is a complex degeneration of the auditory system caused by multiple causes, with risk factors including cochlear aging, environmental factors, genetic susceptibility, family history and comorbidities, especially in noisy environments, noise exposure is the major cause of ARHL.
With the increasing unsafe use of audio equipment and the increasing daily and occupational exposure to noisy environments, the risk of noisy hearing impairment in young 12 to 35 years of age has increased. Not only can cognitive impairment, sleep impairment and cardiovascular health be caused by noise, but hearing impairment can be caused by prolonged exposure to noise at high and moderate sound intensities of 75-85 dB. Even studies have shown that synapses in the auditory structures of the inner ear and spiral ganglia are lost after noise exposure, causing silent hearing impairment and speech recognition impairment.
Noise-induced hearing impairment (NIHL) refers to a temporary or permanent hearing impairment caused by a strong noise stimulus, which may be accompanied by damage to the inner and outer hair cells of the cochlea, the zonal synapses, or the Spiral Ganglia (SGN). Mechanisms associated with noise-induced hearing impairment include abnormalities in ion channels, imbalances in calcium homeostasis, and impairment of oxidative stress, among others.
Autophagy is a major process of degradation of intracellular materials and organelles, and refers to a process in which various components in the cytoplasm are delivered to lysosomes and degraded in the lysosomes, and finally, basic activities and functions of cells are maintained. Autophagy plays an important role in the development of the cochlea, the maintenance of hair cell morphology and auditory function. Autophagy is also thought to be a protective mechanism that limits the triggering of pathological changes in tissues due to stress. Several studies have shown that autophagy plays a role in preventing ototoxic drug-induced hearing impairment, such as that caused by neomycin, gentamicin, or cisplatin. One study has found that the autophagy signaling pathway is involved in the development and progression of NIHL by analyzing the plasma metabolomics of workers exposed to noise. In addition, studies in related rodents have shown that noise exposure promotes autophagy of cochlear hair cells. Some autophagy activators have been shown to reduce oxidative stress damage to the inner ear caused by noise. Rapamycin, a specific mTOR inhibitor, is involved in immunosuppression, affects transcription and protein synthesis, regulates cell growth, apoptosis, etc., and is also an autophagy activator, which has been shown to reduce the level of ROS in the inner ear, thus acting to alleviate oxidative stress injury in the cochlea caused by noise. In addition, peroxisomal phagocytosis, mediated by Pejvakin, can be considered a selective autophagy, and also plays a key role in controlling peroxisome levels and protecting auditory hair cells from noise (85). These studies suggest the importance of autophagy in protecting hearing from noise damage, and there are currently no drugs that protect noise-induced hearing damage directly by enhancing autophagy.
During autophagy, UNC-51-like kinase 1 (ULK 1) is an important kinase for the initiation of autophagy and plays a key role in the initiation of autophagy. The complex of ULK1 with FIP200, ATG13 and ATG101 can initiate autophagosome formation. Activation of ULK1 is regulated by mTORC1 and AMPK. It has been reported that impaired AMPK-mTORC1-ULK1 signaling pathway may play a key role in the degeneration of the auditory cortex. BL-918 is a potent activator of ULK1, and it has been shown in SH-SY5Y cells that BL-918 is effective in preventing the phenotype of mouse Parkinson's model induced by 1-methyl-4-phenylpyridine ion by activating ULK1 to enhance autophagy.
Disclosure of Invention
To solve the problems of the prior art, the present invention aims to provide the application of BL-918 in preventing and/or treating hearing loss, and discloses a novel drug for effectively preventing and/or treating noise-induced hearing loss by enhancing autophagy.
The technical scheme of the invention is as follows:
the present invention provides the use of an ULK1 activator for the prevention and/or treatment of noise-induced hearing impairment, for the protection of hearing, and/or for the treatment of hearing impairment.
Preferably, the ULK1 activator is BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof.
Preferably, the ULK1 activator is used for preventing hearing impairment.
Further, the ULK1 activator was administered 2 days prior to noise exposure.
Further, the administration mode of the ULK1 activator is round window membrane penetration administration.
Further, the dose of the ULK1 activator is 2-200uM and the volume is 2ul. Preferably, the ULK1 activator is administered at a dose of 200uM in a volume of 2ul.
Further, the ULK1 activator is used to enhance ULK1 activity in the cochlea, to enhance autophagy levels in spiral neurons in the cochlea, to reduce noise-induced upward hearing threshold shifts, to improve cochlear hair cell survival rates after noise exposure, or to protect noise-induced reduction of neurosynaptic, among others.
The invention also provides a pharmaceutical composition, which comprises BL-918 or its pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate as described above, and a pharmaceutically acceptable carrier and a medium.
By the scheme, the invention at least has the following advantages:
1. the invention provides a novel small molecule compound which has a prevention and protection effect on hearing impairment, particularly noise-induced hearing impairment, and provides a novel treatment means and approach for the noise-induced hearing impairment. A single administration of BL-918 prior to noise exposure can reduce the threshold shift in mouse hearing after noise.
2. BL-918 is a novel ULK1 activator, and no relevant research report exists at present.
3. BL-918 has good effect of preventing noise hearing loss on noise of a plurality of frequencies, especially has good prevention effect on diseases such as noise deafness and cannon-shocking deafness, and can be used as a medicine and/or health care product for preventing noise hearing loss.
The foregoing description is only an overview of the technical solutions of the present invention, and in order to make the technical solutions of the present invention more clearly understood and to be implemented according to the content of the description, the following description is given with reference to the detailed drawings and the preferred embodiments of the present invention.
Drawings
FIG. 1 shows cochlear tissue pULK1 of the noiseless control group and noiseless laxative group of mice in example 1 S757 Relative levels of protein.
Fig. 2 shows the spiral neuron autophagosome and autophagososome in cochlea of mice in the noise control group and the noise reduction group in example 2, and statistics.
FIG. 3 shows basement membrane staining and statistics of control, BL-918-treated, NK-treated and NK + BL-918-treated mice in example 3.
Fig. 4 shows ABR thresholds 3, 7, and 14 days after noise exposure for the noise-free group and the noise control group and the noise PBS group in example 4.
Fig. 5 shows ABR thresholds 3, 7 and 14 days after noise exposure for the noise-free group and the noise control group and the noise reduction group in example 5.
Fig. 6 shows ABR thresholds 3, 7 and 14 days after noise exposure for the noise-free group and the noise control group and the noise reduction group in example 6.
Detailed Description
The technical solution of the present invention is further described in detail with reference to the following specific examples. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Through years of research on the effect of ULK1, the inventor discovers the relationship between the expression of ULK1 and hearing impairment, and surprisingly discovers that BL-918 can be used as an activator of ULK1 to play roles in preventing hearing impairment and protecting hearing and playing a role in repairing the impaired hearing by activating ULK1 and further confirming from a cell level to a tissue level. The invention particularly provides application of BL-918 in preventing hearing loss, and provides a useful reference for developing a medicine for treating sensorineural hearing loss.
The present invention provides the use of an ULK1 activator for the prevention and/or treatment of noise-induced hearing impairment, for the protection of hearing, and/or for the treatment of hearing impairment. The ULK1 activator can specifically promote the transcription or translation of the ULK1 gene, or can specifically promote the expression or activity of the ULK1 protein, so that the autophagy level in a spiral neuron in a cochlea is enhanced, and the aim of protecting the hearing is fulfilled.
Preferably, the ULK1 activator is BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof. BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof can play a role in protecting hearing by taking ULK1 as a drug action target.
The chemical formula of the BL-918 is C 23 H 15 F 8 N 3 OS, the structure is shown in formula I below:
the invention also provides application of the pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate of BL-918 in preparation of a medicine or kit for preventing and/or treating hearing impairment.
In the application of the present invention, the hearing impairment is sensorineural hearing impairment, and is selected from at least one of the following: ototoxic drugs, noise, genetic, geriatric, metabolic, autoimmune diseases and hearing impairment caused by tumors. Wherein the hearing impairment caused by the noise is noise-induced hearing impairment, including noise-induced deafness and cannon-vibration deafness; the BL-918 can reduce threshold movement of hearing after noise exposure, improve activity of ULK1, improve autophagy level in spiral neurons in cochlea, improve survival rate of cochlear hair cells after noise exposure, protect noise-induced reduction of nerve synapses and the like.
Wherein the noise is broad spectrum noise with frequency of 4-60 kHz and/or intensity of 90-150 dB.
The administration mode of the BL-918 is round window membrane permeation administration; and/or, the BL-918 is administrated in a dose of 2-200uM and a volume of 2ul.
In the application of the invention, the BL-918 is a single effective component of a pharmaceutical preparation. In some embodiments, the pharmaceutical preparation comprises other pharmaceutical ingredients related to hearing protection besides the BL-918 ingredient, and is a pharmaceutical preparation prepared from BL-918 and pharmaceutical excipients. In a specific embodiment, the application of BL-918 in preparing a medicament for preventing and/or treating hearing loss specifically refers to: BL-918 is used as a main effective component of a medicament for preparing a medicament for preventing and/or treating hearing impairment.
In the application of the present invention, the activation or promotion effect of BL-918 on ULK1 includes but is not limited to: promote the gene transcription or expression of ULK1, activate the activity of ULK1, and activate or promote the function of ULK 1. For example, BL-918 can increase the ULK1 content in a cell by 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% without affecting other functions of the cell, as compared to a control.
The invention also provides a pharmaceutical composition for preventing and/or treating hearing impairment, which comprises the ULK1 activator BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof as described above, and a pharmaceutically acceptable carrier or vehicle.
Further, the acceptable carrier, medium such as sterile water or physiological saline, stabilizer, excipient, antioxidant (ascorbic acid, etc.), buffer (phosphoric acid, citric acid, other organic acids, etc.), preservative, surfactant (PEG, tween, etc.), chelating agent (EDTA, etc.), binder, etc. are preferably used. Moreover, other low molecular weight polypeptides may also be present; proteins such as serum albumin, gelatin, and immunoglobulin; amino acids such as glycine, glutamine, asparagine, arginine and lysine; saccharides or carbohydrates such as polysaccharides and monosaccharides; sugar alcohols such as mannitol and sorbitol. When an aqueous solution for injection is prepared, for example, physiological saline, an isotonic solution containing glucose or other auxiliary drugs, such as D-sorbitol, D-mannose, D-mannitol, sodium chloride, may be used in combination with an appropriate solubilizing agent such as alcohol (ethanol, etc.), polyhydric alcohol (propylene glycol, PEG, etc.), nonionic surfactant (Tween 80, HCO-50), etc.
In the pharmaceutical composition of the present invention, the BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof may be a single active ingredient, or may be combined with other active ingredients to form a combined preparation.
In the pharmaceutical composition of the present invention, the content of the active ingredient (ULK 1 activator BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof) is usually a safe and effective amount, which should be adjusted by those skilled in the art, for example, the administration amount of the active ingredient is usually dependent on the body weight of the patient, the type of application, the condition and severity of the disease, for example, the administration amount as the active ingredient may be usually 1 to 1000mg/kg/day, 20 to 200mg/kg/day, 1 to 3mg/kg/day, 3 to 5mg/kg/day, 5 to 10mg/kg/day, 10 to 20 mg/kg/day, 20 to 30mg/kg/day, 30 to 40mg/kg/day, 40 to 60mg/kg/day, 60 to 80mg/kg/day, 80 to 100 mg/kg/day, 100 to 150mg/kg/day, 200 to 500mg/kg/day, or 500 mg/kg/day.
The active ingredient or pharmaceutical composition containing the active ingredient provided by the present invention may be adapted to any form of administration, and may be administered orally or parenterally, for example, by pulmonary, nasal, rectal and/or intravenous injection, more specifically intradermal, subcutaneous, intramuscular, intraarticular, intraperitoneal, pulmonary, buccal, sublingual, nasal, transdermal, vaginal, oral or parenteral administration; the injection administration includes intravenous injection, intramuscular injection, subcutaneous injection and the like, transdermal administration and the like.
As used herein, the dosage form of the pharmaceutical composition is selected from: injection, sterile powder for injection, tablet, pill, capsule, lozenge, spirit, powder, granule, syrup, solution, tincture, aerosol, powder cloud agent, or suppository. One skilled in the art can select a suitable formulation according to the administration mode, for example, a formulation suitable for oral administration may be a formulation including, but not limited to, pills, tablets, chewables, capsules, granules, solutions, drops, syrups, aerosols or dusts, etc., a formulation suitable for parenteral administration may be a formulation including, but not limited to, solutions, suspensions, reconstitutable dry preparations or sprays, etc., a formulation suitable for rectal administration may be usually a suppository, and a formulation suitable for injection may be an injection, a sterile powder for injection, etc.
The present invention further provides a method for the therapeutic or prophylactic treatment of hearing impairment, which comprises administering to a subject (e.g., a mammal) in need thereof an effective amount of BL-918 or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph, solvate or pharmaceutical composition. The method may also be in vitro or non-therapeutic.
The subject or individual to be treated therapeutically or prophylactically is preferably a mammal, such as, but not limited to, a human, primate, livestock (e.g., sheep, cow, horse, donkey, pig), pet (e.g., dog, cat), laboratory test animal (e.g., mouse, rabbit, rat, guinea pig, hamster), or a captured wild animal (e.g., fox, deer). The subject is preferably a primate. The subject is most preferably a human. The subject may be a hearing impaired patient or an individual desiring to prevent hearing impairment.
The BL-918 or the pharmaceutical composition can be administered to a subject before, during, or after receiving a hearing impairment treatment.
In the present invention, the salt or ester of the ULK1 activator BL-918 may be used in the form of a pharmaceutically or physiologically acceptable salt or ester. By "pharmaceutically acceptable salt" is meant, in general, any salt which is physiologically tolerable (in general, it is meant non-toxic, in particular as a result of counterions) when used in a suitable manner in therapy, in particular when applied or used in humans and/or mammals. These physiologically acceptable salts may be formed with cations or bases and in the context of the present invention, especially when administered in humans and/or mammals, they are to be understood as being salts formed by at least one compound provided according to the invention, usually an acid (deprotonated), such as an anion, and at least one physiologically tolerated cation, preferably an inorganic cation. In some embodiments, the salts, esters of BL-918 include, but are not limited to, salts or esters with: hydrochloric acid, hydrobromic acid, sulfuric acid, citric acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, succinic acid, oxalic acid, fumaric acid, maleic acid, oxaloacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, or isethionic acid. Salts of halides are also suitable. Other salts include: salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium.
In the present invention, the term "prodrug" refers to a compound that, when administered by an appropriate method, undergoes a metabolic or chemical reaction in the human body to convert to the active ULK1 activator or a pharmaceutically acceptable salt, ester, isomer, prodrug, polymorph or solvate thereof.
In the present invention, the active compound BL-918 may also be used in combination with other therapeutic agents. For example in combination with one or more ingredients useful for protecting hearing selected from the group consisting of: zuoci pill, liuwei dihuang pill, nicergoline tablet, oryzanol, vincamine sustained release capsule, mecobalamin dispersible tablet, vinpocetine injection, cerebroside carnosine injection, troxerutin injection, deproteinized calf blood extract injection, folium Ginkgo extract tablet, citicoline sodium capsule, etc.
In the present invention, when the active compound is used in combination with other therapeutic agents, the active compound is co-administered with the other therapeutic agents. "coadministration" means simultaneous administration via the same or different routes, or sequential administration via the same or different routes, in the same formulation or in two different formulations. By "sequential" administration is meant having a time difference in seconds, minutes, hours, or days between the administration of two or more different compounds.
In the present invention, the ULK1 activator, a drug or a pharmaceutical composition comprising the same plays a role in protecting hearing by at least one of:
enhancing the activity of ULK 1;
enhancing the level of autophagy in spiral neurons in the cochlea;
reducing noise-induced upward hearing threshold shifts;
improving the survival rate of cochlear hair cells after noise exposure;
protection against noise-induced reduction of synapses, etc.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
References herein to "comprising," "including," and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; i.e., meaning "including but not limited to".
Reference herein to a "therapeutically effective amount" generally refers to an amount which, after an appropriate period of administration, is effective to treat the disease condition as set forth above.
References herein to "therapeutic" and "prophylactic" are to be understood in their broadest sense. The term "therapeutic" does not necessarily imply that the mammal is receiving treatment until complete recovery. Similarly, "prophylactic" does not necessarily mean that the subject will not ultimately be infected with the disease condition. Thus, treatment and prevention includes alleviation of the symptoms of, or prevention or reduction of the risk of, a particular disorder. The term "prevention" is to be understood as reducing the severity of the onset of a particular condition. Treatment may also reduce the severity or frequency of acute episodes of an existing condition.
Reference herein to an "cell" that is impaired by hearing should be understood to be any cell that has been impaired by hearing, or any cell that may suffer from hearing loss.
The compounds of the invention and methods thereof are useful for preventing and/or treating hearing impairment, not only in the early stages of hearing impairment to prevent expansion of the impairment, but also for repair after hearing impairment, and as a prophylactic treatment prior to or after exposure to noise or drugs for a period of time; preferably, the BL-918 according to the present invention is used for preventing hearing impairment.
The invention is further illustrated by the following examples. These examples are intended to illustrate the invention and are not intended to limit the scope of the invention. The procedures, conditions, experimental methods and the like for carrying out the present invention are general knowledge and common general knowledge in the art except for the contents specifically mentioned below, and the present invention is not particularly limited.
Example 1 evaluation of the Activity of BL-918 on the cochlear ULK1 in mice
When the Ser757 site of the ULK1 protein is in a phosphorylated state, the interaction between ULK1 and AMPK is inhibited, thereby inhibiting the activity of ULK 1. Thus, detection of pULK1 S757 The protein level may reflect ULK1 activity, pULK1 S757 A decrease in protein levels can reflect the degree of activation of ULK 1.
Preparing 10mM BL-918 storage liquid: 1mg of BL-918 powder was dissolved in 0.1875ml DMSO liquid.
Preparing 200uM BL-918 solution: a20 uL 10mM BL-918 stock solution was diluted to 100ul with PBS to obtain a 200uM BL-918 solution.
Experimental grouping and experimental procedure:
selecting 3 healthy and normal-hearing male wild type 4-week-old C57BL6/J inbred line mice with the weight of 16-18 g. The left and right ears of the mouse are respectively used as a noise-free control group and a noise-free drug-mixing group. The method comprises the following specific steps:
non-noise control group: the left ear of each mouse was left without any treatment.
The noiseless medicine-beating group: the drug is administered through the round window membrane of the cochlea on the right side of the mouse, namely the round window membrane is exposed through the entrance way behind the ear after the mouse is anesthetized, a proper amount of gelatin sponge (the drug administration concentration is 200uM, the volume is 2 ul) of BL-918 solution is sucked and placed in the round window niche, and the auditory bulb is sealed and sewed. And (5) when the mice are awake, putting the mice back into the cage for feeding after the mice are ensured to be in good state. 2 days after administration, mouse cochlear tissue was sampled, ground, lysed using RIPA lysate (Thermo Fisher Scientific, 89900) to extract total protein, and subjected to immunoblotting after protein quantification by BCA method (picyunnan, P0012). Observing pULK1 by using housekeeping gene protein beta-actin as internal reference S757 Protein and beta-actin protein expression level, calculating pULK1 S757 The ratio of the obtained product to beta-actin is calculated by taking the noiseless control group as 1 to calculate pULK1 of the noiseless drug-taking group S757 Relative quantification of (c).
As shown in fig. 1, pULK1 in cochlea of noiseless typing group S757 The relative protein level is obviously reduced compared with that of a noise-free control group, which indicates that the activity of ULK1 in the cochlea of the noise-free drug-taking group is higher, and BL-918 can enhance the activity of ULK1 in the cochlea.
Example 2 assessment of the ability of BL-918 to activate the level of autophagy of the cochlea in mice
CAG-RFP-EGFP-LC3 transgenic mice have CAG promoter/enhancer sequences that drive the Red Fluorescent Protein (RFP), enhanced Green Fluorescent Protein (EGFP), and microtubule-associated protein 1 light chain 3 α (Map 1LC3a or LC 3) genes. LC3 can be used as a marker of a common autophagosome, and the expression level of the marker directly reflects the autophagy level of a target region. The two fluorophores RFP and EGFP are different in stability to acidic environment, RFP is stable in acidic pH, and EGFP is easily quenched in acidic lysosome environment. After the autophagosome is combined with a lysosome, the autophagosome forms the autophagososome, and the EGFP fluorescence is quenched due to the reduction of the pH value, so that the autophagosome can be distinguished from the autophagososome. That is, yellow fluorescence (RFP and EGFP colocalization) shows autophagosomes, and only red fluorescence, but no green fluorescence, shows autophagosomes. The CAG-RFP-EGFP-LC3 mouse is commonly used for researching autophagy conditions in mouse cells, and can visually detect autophagy levels in different cells in the mouse.
The preparation method of 200uM BL-918 solution is the same as that of example 1.
Experimental grouping and experimental procedures:
3 healthy and normal-hearing male 4-week-old CAG-RFP-EGFP-LC3 transgenic mice with the body weight of 16-18 g are selected. The left ear and the right ear of the mouse are respectively used as a noise control group and a noise typing group. The method comprises the following specific steps:
noise control group: each mouse left ear without any treatment.
A noise medicine-preparing unit: the round window membrane is exposed through the entrance behind the ear after the mouse is anesthetized, gelatin sponge (the administration concentration is 200uM, the volume is 2 ul) which absorbs a proper amount of BL-918 solution is placed in the round window niche, the auditory blister is sealed, and the mouse is sutured. And (5) when the mice revive, putting the mice back into the cage for feeding after the mice are ensured to be in a good state.
After 2 days of dosing, all mice were exposed to a narrow frequency noise environment at a frequency of 8-169khz, 104db SPL for 2 hours, during which the mice were free to move in the noise cage compartment. The material was harvested from 2 groups of mouse cochlea 1 hour after the noise exposure of the mice, the tissue was fixed in 4% paraformaldehyde in the dark for 16 hours at 4 ℃ and then decalcified with 0.5M ethylenediaminetetraacetic acid (EDTA). Then the cochlear tissue is placed in sucrose with the mass percent of 15% and sucrose with the mass percent of 30% to perform tissue gradient dehydration for 1 day respectively, and then the cochlea is put into an OCT embedding medium to be frozen for 12 hours at the temperature of-20 ℃. The mouse cochlea was then subjected to cochlear freezing sectioning with a section thickness of 10um. Then, immunofluorescent staining was performed on the frozen cochlear sections, and both RFP and EGFP signals were autofluorescent, and cochlear spiral neuron cells were visualized using TUJ1 (801202, biolegend) antibody without staining. Changes in the number of autophagosomes (yellow signal) and autophagosomes (RFP signal only) in helical neurons in the mouse cochlea were observed under confocal microscopy.
As shown in fig. 2, the numbers of autophagosomes and autophagosomes in spiral neurons in cochlea of the noise reduction drug group are both significantly increased compared with the control side, which suggests that BL-918 can enhance the autophagy level in spiral neurons of the cochlea of a mouse.
Example 3 BL-918 evaluation of protective action against nerve injury of mouse culture basement membrane
The noise impairment mechanism is thought to be a kind of neuronal excitatory impairment. N-methyl-D-aspartate (NMDA) and Kainic Acid (KA) are potent agonists of excitatory amino acid receptors in nerve cells. NMDA (Tocris) in combination with KA (Sigma) (NK) can cause excitotoxicity of nerve cells, thereby causing nerve damage to the basal membrane of the cochlea in culture. This example uses NK to simulate noise damage to spiral neurons in vitro.
General medium: DMEM/F12 medium (Gibco, 11320033) was added with 1x B27 (Gibco, 17504044) and 1x N2 (Gibco, A1370701).
The medium containing 5uM BL-918 was obtained by adding 5uM BL-918 to a normal medium to a final concentration.
The medium containing NK (containing 0.5mM NMDA and 0.5mM KA) was a medium obtained by additionally adding NMDA and 0.5mM KA to a normal medium to a final concentration of 0.5 mM.
The medium containing NK (containing 0.5mM NMDA and 0.5mM KA) and 5uM BL-918 was obtained by additionally adding NMDA, 0.5mM KA and 5uM BL-918 to a common medium to a final concentration of 0.5 mM.
6 wild-type post-natal day 2 (P2) C57BL6/J inbred mice were selected, the cochlear basilar membranes of the left and right ears were dissected and cultured at 37 ℃,5% CO2 for 24 hours, and 12 cochlear basilar membranes were randomly divided into four groups: control group, BL-918 treatment group, NK + BL-918 treatment group.
Control group: no treatment is carried out;
BL-918 processing group: incubate 20 hours with medium containing 5uM BL-918;
NK treatment group: incubating with medium containing NK (containing 0.5mM NMDA and 0.5mM KA) for 2 hours, and then replacing with common medium for 18 hours;
NK + BL-918 processing group: first, incubation was performed for 2 hours with medium containing both NK (0.5 mM NMDA and 0.5mM KA) and 5uM BL-918, followed by a change to medium containing 5uM BL-918 and incubation continued for 18 hours.
The cultured basement membrane was then fixed and immunostained to observe the attachment of inner hair cells, nerve fibers and inner hair cells, and inner hair cells were visualized using Myosin VIIa (# 25-6790, protein BioSciences Inc) and NF-H (# AB5539, millipore) to visualize the nerve fibers attached to the inner hair. And calculating the number of nerve fibers linked with each inner hair cell so as to evaluate the damage condition of the basal lamina nerve.
As shown in fig. 3, the ordinate means the number of nerve fibers connected per inner hair cell. As a result, the numbers of nerve fibers connected to inner hair cells in the BL-918-treated group and the control group were similar, indicating that BL-918 is not toxic in vivo. Compared with the control group, the number of nerve fibers connected with each inner hair cell of the basement membrane of the mice in the NK treatment group is obviously reduced, which indicates that the NK treatment damages the nerve fiber connection of the inner hair cells of the basement membrane of the mice, and is similar to the previous report. The number of nerve fibers connected with each inner hair cell in the NK + BL-918 treatment group is obviously increased compared with that in the NK treatment group, and the fact that BL-918 can protect nerve fiber damage caused by NK is proved.
Example 4 evaluation of the protective Effect of PBS buffer on noise-induced hearing impairment in mice
Selecting 8 healthy and normal-hearing male wild type 4-week-old C57BL6/J inbred line mice with the weight of 16-18 g.
The method comprises the following specific steps:
noise-free group: the left ear hearing was tested in 4 mice without any treatment.
The other 4 mice were noise group, and the left and right ears were noise control group and noise administration group, respectively. Noise control group: the left ear of another 4 mice was not treated with drug and 2 days later, noise exposure was performed. The 4 mice were treated as a noisy PBS group: the round window membrane is exposed through the entrance behind the ear after the mouse is anesthetized, gelatin sponge (the administration volume is 2 ul) which absorbs a proper amount of 1xPBS buffer solution is placed in the round window niche, the auditory cyst is sealed, and the mouse is sutured. And (3) waiting for the mice to wake up, returning the mice to a cage for feeding after the mice are ensured to be in good state, and exposing noise after 2 days.
Noise group mice noise exposure method: mice were exposed to a narrow-band noise environment with a frequency of 8-16kHz and an intensity of 104dB SPL for 2 hours 2 days after dosing, during which the mice were free to move in the noise cage compartment.
The cochlear hearing threshold of mice was measured by conducting an auditory brainstem response test. And then measuring the hearing threshold values of the left cochlea and the right cochlea of the mice in the noise group on 3 rd, 7 th and 14 th days after the noise exposure of the mice respectively, namely detecting the hearing threshold value change of the noise control group and the noise reduction group to measure the noise damage degree and the medicine protection effect.
As shown in fig. 4, at 3, 7, and 14 days after noise exposure, no noise protection was observed for the noisy PBS dosing group.
Example 5 evaluation of protective Effect of high concentration of BL-918 on noise-induced hearing impairment of mice
8 healthy and normal-hearing male wild type 4-week-old C57BL6/J inbred line mice with the weight of 16-18 g are selected.
The method comprises the following specific steps:
noise-free group: the left ear hearing was tested in 4 mice without any treatment.
The other 4 mice were noise group, and the left and right ears were noise control group and noise administration group, respectively. Noise control group: the left ear of another 4 mice was not treated with drug and 2 days later, noise exposure was performed. The right ear of the 4 mice served as the noise-fighting group: the administration is carried out through the round window membrane of the cochlea on the right side of the mouse, namely the round window membrane is exposed through the entrance of the ear after the mouse is anesthetized, a proper amount of gelatin sponge (the administration concentration is 200uM, the volume is 2uL, the preparation method is the same as that of the example 1) of BL-918 solution is absorbed and placed in the round window niche, the auditory vesicle is sealed, and the suture is carried out. And (3) waiting for the mice to wake up, putting the mice back into a cage to be raised after the mice are ensured to be in good state, and exposing noise after 2 days.
The noise exposure method for the noise group mice comprises the following steps: mice were exposed to a narrow-band noise environment with a frequency of 8-16kHz and an intensity of 104dB SPL for 2 hours 2 days after dosing, during which the mice were free to move in the noise cage compartment.
Cochlear hearing thresholds were measured in mice by performing an auditory brainstem response test. And then measuring the hearing threshold values of the left cochlea and the right cochlea of the mice in the noise group on 3 rd, 7 th and 14 th days after the noise exposure of the mice respectively, namely detecting the hearing threshold value change of the noise control group and the noise reduction group to measure the noise damage degree and the medicine protection effect.
As shown in fig. 5, in 3, 7, and 14 days after the noise exposure, the hearing threshold shift of the inner ear of the mice in the noise drug group is reduced, and compared with the noise control group, the hearing threshold shift of about 20dB SPL is reduced, which proves that 200uM BL918 has a protective effect on the noise hearing impairment of the inner ear of the mice.
Example 6 evaluation of protective Effect of Low concentration BL-918 on noise-induced hearing impairment in mice
Preparing a 2uM BL-918 solution: a20 ul 10mM BL-918 stock solution was diluted to 10000ul with PBS to obtain 200uM BL-918 solution.
Selecting 8 healthy and normal-hearing male wild type 4-week-old C57BL6/J inbred line mice with the weight of 16-18 g.
The method comprises the following specific steps:
noise-free group: the left ear hearing was tested in 4 mice without any treatment.
The other 4 mice were noise group, and the left and right ears were noise control group and noise administration group, respectively. Noise control group: the left ear of another 4 mice was not treated with drug and noise exposure was performed 2 days later. The right ear of the 4 mice served as the group of the noise-fighting drugs: the administration is carried out through the round window membrane of the cochlea on the right side of the mouse, namely the round window membrane is exposed through the entrance of the ear after the mouse is anesthetized, a proper amount of gelatin sponge (the administration concentration is 2uM, the volume is 2ul, the preparation method is the same as that of the example 1) of BL-918 solution is absorbed and placed in the round window niche, the auditory vesicle is sealed, and the suture is carried out. And (3) when the mice revive, putting the mice back into the cage to be raised after the mice are ensured to be in good state, and exposing noise after 2 days.
The noise exposure method for the noise group mice comprises the following steps: mice were exposed to a narrow frequency noise environment with a frequency of 8-16kHz at an intensity of 104dB SPL for 2 hours 2 days after dosing, during which the mice were free to move in the noise cage compartment.
The cochlear hearing threshold of mice was measured by conducting an auditory brainstem response test. And measuring the hearing threshold values of the left cochlea and the right cochlea of the mice in a noise group on 3 rd, 7 th and 14 th days after the noise exposure of the mice is finished, namely detecting the hearing threshold value change of a noise control group and a noise beating group to measure the noise damage degree and the protection effect of the medicines.
As shown in fig. 6, 3, 7, and 14 days after the noise exposure, the hearing threshold shift of the inner ear of the mice in the noise reduction group was observed to be reduced, and compared with the noise control group, the hearing threshold shift of about 20dB SPL was reduced, which proves that the 2uM BL918 has a protective effect on the noise hearing impairment of the inner ear of the mice.
The above examples are only intended to illustrate the technical solution of the present invention and not to limit it; although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art will understand that: modifications to the specific embodiments of the invention or equivalent substitutions for parts of the technical features may be made; variations and advantages which may occur to those skilled in the art without departing from the spirit and scope of the inventive concept are intended to be included within the scope of the invention as claimed.
Claims (11)
- Application of BL-918 or pharmaceutically acceptable salts thereof in preparing medicines for preventing hearing impairment.
- 2. The use of claim 1, wherein said BL-918 has a chemical formula C 23 H 15 F 8 N 3 OS, the structure is shown in formula I below:
- 3. the use of claim 1, wherein the hearing impairment is sensorineural hearing impairment.
- 4. The use of claim 3, wherein the sensorineural hearing impairment is selected from at least one of the following: hearing impairment due to noise, ototoxic drugs, hereditary, senile, metabolic, autoimmune diseases and tumors.
- 5. Use according to claim 3, wherein the sensorineural hearing impairment is noise-induced hearing impairment and/or NK-induced hearing impairment.
- 6. The use of claim 5, wherein the noise-induced hearing impairment is noise-induced hearing impairment, including noise-induced deafness and cannon-induced deafness; and/or, the noise refers to the noise with the frequency of 4-60 kHz and the intensity of 90-150 dB.
- 7. The use according to any one of claims 1 to 6, wherein the medicament acts to protect hearing by at least one of:enhancing the activity of ULK 1;enhancing the level of autophagy in helical neurons in the cochlea;reducing noise-induced upward hearing threshold shifts;improving the survival rate of cochlear hair cells after noise exposure;the noise-induced reduction of the synapses is preserved.
- 8. The use of claim 1 or 2, wherein said BL-918 is administered by round window membrane permeation; and/or, the BL-918 is administrated in a dose of 2-200uM and a volume of 2ul.
- 9. A pharmaceutical composition for preventing hearing impairment, which comprises BL-918 as claimed in claim 1 or 2, and a pharmaceutically acceptable carrier, vehicle.
- 10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is administered in combination with at least one of a hearing protection related drug.
- 11. The pharmaceutical composition of claim 9 or 10, wherein the drug acts to protect hearing by at least one of:enhancing the activity of ULK 1;enhancing the level of autophagy in spiral neurons in the cochlea;reducing noise-induced upward hearing threshold shifts;improving the survival rate of cochlear hair cells after noise exposure;and (3) neural synapse reduction caused by protection noise.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111530607.7A CN114246949B (en) | 2021-12-14 | 2021-12-14 | Use of ULK1 activators for the prevention and/or treatment of hearing impairment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111530607.7A CN114246949B (en) | 2021-12-14 | 2021-12-14 | Use of ULK1 activators for the prevention and/or treatment of hearing impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114246949A CN114246949A (en) | 2022-03-29 |
| CN114246949B true CN114246949B (en) | 2023-02-17 |
Family
ID=80792279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111530607.7A Active CN114246949B (en) | 2021-12-14 | 2021-12-14 | Use of ULK1 activators for the prevention and/or treatment of hearing impairment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114246949B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024030332A1 (en) * | 2022-08-01 | 2024-02-08 | Verge Analytics, Inc. | Methods of treating neurological disorders with activators of unc51-like autophagy activating kinase 1 (ulk1) |
| CN119700734A (en) * | 2025-02-11 | 2025-03-28 | 山东大学齐鲁医院 | Application of BL-918 in the preparation of 2K drugs for the treatment of Charcot-Marie-Tooth disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051845A (en) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | A kind of mTOR inhibitors, pharmaceutical composition and its application |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3618807A4 (en) * | 2017-05-03 | 2021-01-20 | Jian Zuo | HEARING LOSS PREVENTION COMPOSITIONS AND METHODS |
-
2021
- 2021-12-14 CN CN202111530607.7A patent/CN114246949B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110051845A (en) * | 2018-01-19 | 2019-07-26 | 沈阳福洋医药科技有限公司 | A kind of mTOR inhibitors, pharmaceutical composition and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114246949A (en) | 2022-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | Autophagy activation is involved in neuroprotection induced by hyperbaric oxygen preconditioning against focal cerebral ischemia in rats | |
| US8507525B2 (en) | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | |
| US20210283108A1 (en) | Method for treating neurodegenerative diseases | |
| EP1729753B1 (en) | Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity | |
| CN114246949B (en) | Use of ULK1 activators for the prevention and/or treatment of hearing impairment | |
| US8053424B2 (en) | Composition and method of treating hearing loss | |
| US10966940B2 (en) | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | |
| CA3054992A1 (en) | Prevention of the risks associated with drug-induced qt interval prolongation by using a specific inhibitor of the production of ros of mitochondrial origin | |
| TW201609640A (en) | Use of indolyl and indolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits | |
| US20060280812A1 (en) | Compositions and methods for the treatment of muscular dystrophy | |
| CN113855803B (en) | Use of PRMT5 inhibitors for the preparation of hearing protection medicaments | |
| US8481500B2 (en) | Compounds having neuroprotective properties | |
| CN117323312B (en) | Composite material and preparation method and application thereof | |
| TW202400127A (en) | Use of a composition for manufacture of a medicament for preventing or treating hearing loss | |
| van Megen et al. | The effect of the CCK-B receptor antagonist CI-988 on CCK-4 induced panic attacks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |